

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **CanSino Biologics Inc.**

### **康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

## **VOLUNTARY ANNOUNCEMENT ENTERING INTO COLLABORATION AGREEMENT**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the Company and BIRD-C GmbH (“**BIRD-C**”) entered into a research and development collaboration agreement (the “**Collaboration Agreement**”), pursuant to which the parties shall collaborate with one another to explore (i) Bacterial Ghosts (“**BGs**”) as standalone adjuvant to the Company’s vaccines; and (ii) bacterial antigen expressing directly in E. coli carrier BGs to produce new vaccines.

BIRD-C is a company with limited liability incorporated in Vienna, Austria and offers solutions for delivery of biologically active substances, vaccines and adjuvants against emerging and existing infectious and life threatening diseases with focus on BGs cancer immunotherapy.

To the best of the Company’s knowledge, information and belief, and having made all reasonable enquiries, BIRD-C and its ultimate beneficial owners are all third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Company believes that the Collaboration Agreement will establish a framework for the exchange of professional knowledge, experience and for future cooperation on research, development and commercialization in areas of human use vaccine field, and enhance strategic cooperation between the activities of the Company and BIRD-C, both in China and abroad.

The Company will work closely with BIRD-C to conduct all preclinical and clinical studies of new vaccines, and be responsible for commercial manufacturing, sales and marketing of the new vaccines. During the term of the Collaboration Agreement, the Company will have an exclusive worldwide permanent right (including all intellectual properties owned, developed or acquired by BIRD-C (the “**BIRD-C IP rights**”)) for any new vaccine expressed by BIRD-C using E. coli BGs as carrier and a non-exclusive world-wide permanent rights (including all BIRD-C IP rights) for using BGs as standalone adjuvants.

**Shareholders and potential investors should exercise caution when investing in or dealing in the securities of the Company.**

For and on behalf of  
**CanSino Biologics Inc.**  
**Xuefeng YU**

*Chairman and chief executive officer*

Hong Kong, June 12, 2019

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Dr. Zheng YIN as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Dr. Luis BARRETO and Dr. Pierre Armand MORGON as independent non-executive Directors.*